Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779619 | 0.88 | HRH3 (0.43) | OPRD1OPRK1HRH3ALDH1A1KDM4E | |
| SCHEMBL6783715 | 0.82 | MLNR (0.48) | OPRM1OPRD1OPRK1HRH3ALDH1A1 | |
| SCHEMBL6781033 | 0.80 | FAAH (0.48) | OPRM1OPRK1HRH3KMT2ASIGMAR1 | |
| SCHEMBL6784382 | 0.78 | FAAH (0.52) | OPRK1HRH3KMT2AMLNR | |
| SCHEMBL6780210 | 0.75 | HRH3 (0.45) | HRH3ALDH1A1MLNR | |
| SCHEMBL6782805 | 0.71 | HRH2 (0.52) | OPRD1OPRK1ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL7221992 | 0.71 | ALDH1A1 (0.46) | MAPK1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL6784044 | 0.68 | KMT2A (0.51) | MAPK1ALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL6784066 | 0.67 | HTR2A (0.47) | ALDH1A1 | |
| SCHEMBL6779964 | 0.67 | SMN1; SMN2 (0.53) | ALDH1A1KMT2ASIGMAR1MAPTGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | SCN5A, RYR2, SCN1B | MAPK1 721/4885LIPE 2258/4885OPRM1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.